Fundamental, Research

Drug Distributors: Prescription Volumes, New Therapies Powering Higher Stock Prices

Daniel Rich, CFA, Equity Analyst
28 December 2023


Drug distributors McKesson Corporation (MCK), Cencora Inc. (COR), and Cardinal Health Inc.(CAH) have been performing significantly better than the healthcare sector. This is because they have been selling a large quantity of pharmaceuticals. However, the distribution of GLP-1 drugs has been boosting their revenues at the cost of their profit margins. These distributors are also benefiting from new therapies in biopharma, especially in the field of oncology. This is resulting in new business opportunities for them. Although the multiples have expanded and are currently trading at premiums to recent historical levels, we believe that the valuations are justified in the current operating environment.

Want to learn more? Download the Report.


Fundamental Equity Research
Gain a comprehensive view of global themes, industries, and companies.

Related Insights

Consumer Staples: Risks From Anti-Obesity Medications Likely Overblown

Consumer Staples: Risks From Anti-Obesity Medications Likely Overblown

Anti-obesity medications (AOMs), including glucagon-like peptide-1 (GLP-1) agonists...
Read more